Web Watch

Share this article:
Looking for credible health information on the Internet is getting much easier, if you know where and how to look for it.

While search technology has matured quite a bit over the past few years, we are still experiencing what some media insiders refer to as “crap overload.” Or, as Linda Holliday of Medical Broadcasting Company says, “We're building quite a big haystack on the Web.”

Finding the “needle” is often a difficult challenge.

It can be argued that health information seekers get a bigger benefit from search technology than most other vertical information segments. Two-thirds of all people in the US search the Internet before and after a visit to their physician according to a Nielsen/Net Ratings survey.

Almost a third of all respondents in the study said they visited a pharma site.

Google delivers a big haystack in which to find the “needle” but hasn't released a search site for healthcare. Meanwhile, newer sites like Kosmix.com and Healia.com claim to be more effective and efficient at searching for health information.

Healthline (www.healthline.com) appears to be one of the more well-rounded search portals. It does a good job of integrating content and health channels alongside its search feature. Healthline's special sauce, according to company President Dean Stephens, is its semantic taxonomy that was designed by physicians and medical informatics experts.

The challenge specialized search services need to solve is to educate people how to conduct better searches. More than 90% of people conducting searches don't go beyond the first two search page results. And, only 3% of searchers use quote marks to search an exact phrase. Finding that needle in the haystack isn't all that hard if you know how and where to look.

Dan McKillen is president of the HealthDay news service

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...